Outcome of severe to critical COVID-19 patients with tocilizumab therapy
DOI:
https://doi.org/10.18203/2349-3933.ijam20242308Keywords:
COVID-19, Tocilizumab therapy, Standard therapyAbstract
Background: The inflammatory response plays a critical role in COVID 19 and inflammatory cytokine storm increases the severity of COVID-19. Tocilizumab, an IL-6 receptor monoclonal antibody, has been used for the treatment of patients with COVID-19. This study compared the outcome of tocilizumab therapy with other standard therapy in the management of severe to critical COVID-19 patients.
Methods: This observational prospective comparative study was conducted at the COVID-19 unit of Bangabandhu Sheikh Mujib medical university (BSMMU), for one year period following approval of this protocol. A total of 60 severe to critical COVID-19 patients were enrolled in this study and categorized into two groups: Tocilizumab along with standard therapy (n=30) and another group receiving standard therapy only (n=30). After taking written informed consent, a detailed history and thorough clinical examination were carried out along with relevant investigations. After the collection of all the required data, analysis was done by SPSS 24.0.
Results: The study's predominantly male patients (mean age 53.7±11 years) had high rates of hypertension (63.3%) and diabetes (48.3%), with most experiencing severe COVID-19 (76.6%). Initial similarities in both groups included socio-demographics and disease severity (p>0.05). After 2 weeks, the tocilizumab group had lower WBC counts (5.15±2.39 vs 7.56±1.47×109/l), lower CRP levels (2.7±0.93 vs 7.5±2.38 mg/l, p<0.05), shorter hospital stays (18.25±4.58 vs 25.4±2.70 days, p=0.005), reduced oxygen requirements (7.25±4.23 vs 12±7.29%, p=0.005), and lower mortality (40% vs 66.66%, p=0.027).
Conclusions: Tocilizumab therapy has better outcomes in severe to critical COVID-19 patients. However, a further larger study is recommended.
References
Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, et al. Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia. Front Immunol. 2021;12:613422.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-73.
Mahat RK, Panda S, Rathore V, Swain S, Yadav L, Sah SP. The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Epidemiol Global Heal. 2021;11:100727.
DGHS, 2021. Coronavirus COVID-19 Dashboard. Viewed 7 September, 2022. Available at: https://dghs-dashboardcom.translate.goog/pages/covid19.php?_x_tr_sl=bn&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc. Accessed on 12 June, 2024.
World Health Organization (WHO), 2022. COVID-19 report. Viewed on 7 September, 2022. Available at: https://www.who.info/coronavirus/covid-19report/>. Accessed on 12 June, 2024.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.
Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings National Academy Sci. 2020;117(20):10970-5.
Tomasiewicz K, Piekarska A, Stempkowska-Rejek J, Serafińska S, Gawkowska A, Parczewski M, et al. Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. Expert Rev Anti Infect Therapy. 2021;19(1):93-100.
Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2(10):603-12.
Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmunity Rev. 2020;19(7):102568.
Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emergency Med. 2020;38(9):1722-6.
Gómez-Pastora J, Weigand M, Kim J, Wu X, Strayer J, Palmer AF, et al. Hyperferritinemia in critically ill COVID-19 patients-Is ferritin the product of inflammation or a pathogenic mediator? Clin Chimica Acta. 2020;509:249-51.
Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):474-84.
Abdelnaby H, Aboelhassan W, Al‐Jarallah M, Rajan R, Dashti R, Zhanna KD, et al. Outcomes of tocilizumab therapy in severe or critical COVID‐19 patients: A retrospective cohort, single‐centre study. Trop Med Int Health. 2021;26(12):1689-99.
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Eng J Med. 2020;383(24):2333-44.
Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrobial Agents. 2020;56(3):106103.
Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Translational Med. 2020;18(1):1-8.
Lia Q, Dinga X, Xiab G, Chend HG, Chena F, Genga Z. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study. E-Clin Med. 2020;23:100375.
Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: Randomised controlled trial. The BMJ. 2021;372:n84.
